In this episode of the Endpoints Podcast, Dr. Theo Hatzipetros, the Director of Pharmacology at the ALS Therapy Development Institute (ALS TDI) joins us to discuss CMAP and the role it now plays at the lab. CMAP, which stands for Compound Muscle Action Potentials, is a technique used by neurologists to diagnose neuromuscular diseases and monitor disease progression. In mouse models of ALS used at the ALS TDI lab, CMAP can be used to detect and track disease progression before signs would be noticeable by Neuroscore, the traditional way of monitoring disease progression that relies on the human eye to detect it. Detecting signs of ALS earlier allows researchers to determine the efficacy of potential drugs quicker and ensures that the best drug candidates are advanced to the next stage for further testing.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.